Results for tag: "Minimally Invasive Glaucoma Surgery Devices"

Minimally Invasive Glaucoma Surgery (MIGS) devices are a subset of surgical devices designed for the treatment of glaucoma, a chronic eye condition that leads to increased intraocular pressure (IOP) and can result in vision loss. These devices offer a less invasive alternative to traditional glaucoma surgeries, aiming to reduce IOP by improving aqueous humor outflow from the eye. MIGS procedures typically involve micro-scale incisions and implants, promising reduced recovery times and a lower risk of complications compared to conventional surgical methods. The market for MIGS devices overlaps with the broader ophthalmic surgical device market and aligns with an increasing demand for surgeries that provide symptom relief while minimizing tissue trauma. The development and adoption of MIGS devices have been influenced by technological advances, the rising prevalence of glaucoma, and the prioritization of patient quality of life and surgical outcomes. As a niche within surgical devices, MIGS products often require specialized training for surgeons and are accompanied by ongoing research and development to optimize their efficacy and safety profiles. In the market for MIGS devices, several companies are prominent, including Glaukos Corporation, Ivantis Inc., Alcon, a division of Novartis, and Johnson & Johnson Vision, a subsidiary of Johnson & Johnson. Other players include Allergan (now part of AbbVie), and New World Medical, which also contribute to the research, development, and distribution of these specialized surgical instruments for gl Show Less Read more